Durgadevi Ravillah, Ph.D.
Affiliations: | 2013 | University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States |
Area:
Pathology, Oncology, Cell BiologyGoogle:
"Durgadevi Ravillah"Parents
Sign in to add mentor| Chinthalapally V. Rao | grad student | 2013 | University of Oklahoma Health Sciences Center | |
| (HDAC2 in colon tumor progression and as a potential target for chemoprevention and treatment.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Janakiram NB, Mohammed A, Ravillah D, et al. (2025) [Corrigendum] Chemopreventive effects of PBI‑Se, a selenium‑containing analog of PBIT, on AOM‑induced aberrant crypt foci in F344 rats. Oncology Reports. 53 |
| Blum AE, Venkitachalam S, Ravillah D, et al. (2019) Systems Biology Analyses Reveal Hyperactivation of Transforming Growth Factor beta and JNK Signaling pathways in Esophageal Cancer. Gastroenterology |
| Ravillah D, Mohammed A, Qian L, et al. (2014) Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis. The Journal of Pharmacology and Experimental Therapeutics. 348: 59-68 |
| Das DS, Tian Z, Ray A, et al. (2014) Anti-Myeloma Activity of a Novel Free Radical Inducer Rrx-001 Blood. 124: 4712-4712 |
| Song Y, Das DS, Ray A, et al. (2014) Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 in Multiple Myeloma Blood. 124: 419-419 |
| Ray A, Das DS, Ravillah D, et al. (2014) SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Blocks Plasmacytoid Dendritic Cell (pDC)-Triggered Myeloma Cell Growth and Prevents Osteoclastogenesis Blood. 124: 3441-3441 |
| Das DS, Ravillah D, Ray A, et al. (2014) Anti-Myeloma Activity of a Novel Glutaminase Inhibitor CB-839 Blood. 124: 3439-3439 |
| Das DS, Ravillah D, Ray A, et al. (2014) Synergistic Anti-Myeloma Activity of a Proteasome Inhibitor Marizomib and IMiD® Immunomodulatory Drug Pomalidomide Blood. 124: 2099-2099 |
| Ray A, Ravillah D, Das DS, et al. (2014) A Novel Alkylating Agent Melphalan Flufenamide Ethyl Ester Induces an Irreversible DNA Damage in Multiple Myeloma Cells Blood. 124: 2086-2086 |
| Janakiram NB, Mohammed A, Ravillah D, et al. (2013) Chemopreventive effects of PBI-Se, a selenium-containing analog of PBIT, on AOM-induced aberrant crypt foci in F344 rats. Oncology Reports. 30: 952-60 |